临床肺炎克雷伯菌多黏菌素耐药通过多样遗传适应出现:基因组回顾性队列研究
该回顾性队列研究纳入2011-2018年88例多黏菌素耐药肺炎克雷伯菌患者,对388株分离株(含164株耐药株)行全基因组测序,分析mgrB、crrAB、phoPQ和pmrAB等关键基因变异。结果显示耐药机制高度异质,60%(53/88)患者有多黏菌素暴露史,暴露后新发耐药而非传播是多数患者耐药的主要原因。
要点
- 多黏菌素耐药机制高度异质,即使在同一簇或同一患者内也存在多种遗传事件。
- 60%(53/88)患者在检出耐药前有多黏菌素暴露,提示暴露后新发耐药为主。
- 优化多黏菌素使用是阻止耐药传播的关键策略。
核心结论
- 临床肺炎克雷伯菌多黏菌素耐药的分子机制高度异质,即使在同一簇或同一患者内亦然。
- 多数患者的多黏菌素耐药由暴露后新发耐药导致,而非传播。
- 优化多黏菌素使用应是阻止耐药传播的关键策略。
研究设计与样本
- 回顾性队列研究纳入2011-2018年88例多黏菌素耐药肺炎克雷伯菌患者,收集人口学、抗菌药物暴露和感染数据。
- 对388株分离株(含164株耐药株)行全基因组测序,对mgrB、crrAB、phoPQ和pmrAB进行变异检测和插入序列检测。
- 对关键多位点序列型ST258、ST17、ST307和ST392进行系统发育分析。
主要发现
- 53/88(60%)患者在检出多黏菌素耐药前有多黏菌素暴露记录。
- 在耐药分离株中检出129个独立变异和72种独特变异组合,36%有连续耐药分离株的患者存在多个不同改变。
- 插入序列破坏仅限于mgrB(P < .001)。
- 多黏菌素最低抑菌浓度随受累耐药基因数量增加呈阶梯式上升(P < .001)。
- 在含≥2例患者耐药分离株的簇中,10/14簇存在多个导致耐药的遗传事件。
临床怎么用
- 对有多黏菌素暴露史的患者应警惕耐药新发,而非仅考虑传播。
- 优化多黏菌素使用可作为遏制耐药传播的关键策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polymyxins are antimicrobials of last resort for the treatment of carbapenem-resistant Enterobacteriaceae, but resistance in 5% to >40% isolates has been reported. We conducted a genomic survey of clinical polymyxin-resistant (PR) Klebsiella pneumoniae to determine the molecular mechanisms of PR and the role of polymyxin exposure versus transmission in PR emergence. METHODS: We included 88 patients with PR K. pneumoniae from 2011-2018 and collected demographic, antimicrobial exposure, and infection data. Whole-genome sequencing was performed on 388 isolates, including 164 PR isolates. Variant calling and insertion sequence detection were performed, focusing on key genes associated with PR (mgrB, crrAB, phoPQ, and pmrAB). We conducted phylogenetic analyses of key K. pneumoniae multi-locus sequence types (ST258, ST17, ST307, and ST392). RESULTS: Polymyxin exposure was documented in 53/88 (60%) patients prior to PR detection. Through an analysis of key PR genes, we detected 129 individual variants and 72 unique variant combinations in PR isolates. This included multiple, distinct changes in 36% of patients with serial PR isolates. Insertion sequence disruption was limited to mgrB (P < .001). Polymyxin minimum inhibitory concentrations showed stepwise increases with the number of PR genes affected (P < .001). When clusters containing PR isolates in ≥2 patients were analyzed, 10/14 had multiple genetic events leading to PR. CONCLUSIONS: Molecular mechanisms leading to PR in clinical K. pneumoniae isolates are remarkably heterogenous, even within clusters or individual patients. Polymyxin exposure with de novo PR emergence led to PR in the majority of patients, rather than transmission. Optimizing polymyxin use should be a key strategy in stopping the spread of PR.
引用
- Macesic N, Nelson B, Mcconville TH, et al. Emergence of Polymyxin Resistance in Clinical Klebsiella pneumoniae Through Diverse Genetic Adaptations: A Genomic, Retrospective Cohort Study. Clin Infect Dis. 2020. PMID: 31513705. doi:10.1093/cid/ciz623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。